News | December 12, 2007

WorldHeart Enters Strategic Alliance With Abiomed

December 13, 2007 - World Heart Corp., a developer of implantable mechanical circulatory support systems for chronic heart failure patients, announced its strategic alliance with Abiomed Inc., a leading manufacturer of devices for acute circulatory support.

WorldHeart and Abiomed currently serve complementary segments of the circulatory support market. This alliance is expected to benefit heart failure patients and treatment providers, promoting synergies between the two organizations in a number of areas, including:

- Products - WorldHeart's Novacor pulsatile LVAS and the Levacor Rotary VAD are designed to provide long-term support for chronic heart failure patients. Intended for use as a bridge to transplant or for destination (life-long) therapy, implant durations typically range from months to years. Abiomed markets a number of devices targeting primarily recovery applications,where support duration is measured in hours, days or months.The portfolios of the two companies collectively span the full spectrum of mechanical circulatory support needs, with implant durations ranging from hours to years, and from partial to total support.
- Clinical Relationships - The recipients of WorldHeart's chronic support devices are under the care of heart failure cardiologists and cardiac surgeons. Abiomed's products are administered by interventional cardiologists as well as cardiac surgeons.Collectively, the two companies have access to a broad base of clinical customers addressing a wide range of cardiac conditions.
- Marketing and Clinical Support - The two companies expect to be able to reach a broader customer base and provide an efficient and high level of clinical support.
- Technology - The companies also expect to explore opportunities for technology collaborations. The transcutaneous (across-the-skin) energy transfer system and implanted electronics developed for the AbioCor total heart potentially could be adapted to the Levacor, eliminating any wires through the skin to reduce the associated infection risk.

For more information: www. worldheart.com, www.abiomed.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init